[Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer]
| Autor: | Koichiro Akakura, Susumu Akimoto, Manabu Kuriyama, Jun Shimazaki, Yukimichi Kawada, Takemasa Ohki |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
PCA3
Male medicine.medical_specialty Urology medicine.medical_treatment Early detection Sensitivity and Specificity Prostate cancer Total prostatectomy medicine Biomarkers Tumor Doubling time Humans Aged Aged 80 and over Prostatectomy business.industry Endocrine therapy Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Combined Modality Therapy Radiation therapy Prostate-specific antigen Evaluation Studies as Topic Reagent Kits Diagnostic business |
| Zdroj: | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 86(2) |
| ISSN: | 0021-5287 |
| Popis: | Prostate specific antigen (PSA) levels after total prostatectomy or radiation therapy to localized prostate cancer and also during endocrine therapy are within normal range. Therefore, it is necessary to use hyper sensitive PSA assay kits for early detection of relapse. The present study was undertaken to evaluate two hyper sensitive assay kits (Delfia kit, lower limit 0.1 ng/ml, Kabi Pharmacia Diagnostics Co. and Markit M kit, 0.5 ng/ml, Dainippon Pharmaceutical Co.) and to compare them with conventional PSA kit (Eiken Chemical Co., 1.0 ng/ml). Total of 291 sera were examined: patients consisted of 10 total prostatectomy+endocrine therapy, 9 radiation therapy+endocrine therapy, 5 radiation therapy alone and 44 endocrine therapy alone. Values of endocrine therapy alone were divided into two groups according to duration after start of treatment; more or less than 5 years. The following results were obtained. 1. In non-relapse patients after total prostatectomy+endocrine therapy and radiation+endocrine therapy, PSA showed under lower limit with hyper sensitive kit. On the contrary, conventional kit indicated more than 1.0 ng/ml. 2. Radiation therapy alone kept PSA in detectable range with hyper sensitive kit in spite of no sign of relapse. 3. In non-relapsed patients under endocrine therapy alone, long duration (more than 5 years after start of treatment) decreased PSA in non detectable values with hyper sensitive kits. In this case, conventional kit still showed PSA as more than 1 ng/ml. 4. Doubling time at relapse was estimated similar with Delfia kit and Markit M kit, and much longer with conventional kit. It is concluded that hyper sensitive kit is more useful to manage patients after therapy than conventional kit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|